State employees: covered by law since July 1, 2024
Illinois law requires the State Employees Group Insurance Program to cover "medically necessary" injectable medicines "prescribed on-label or off-label to improve glucose or weight loss" for adults diagnosed with "prediabetes, gestational diabetes, or obesity" (5 ILCS 375/6.11C). The state's CVS Caremark drug list, effective October 1, 2026, carries Zepbound®, Wegovy® and Foundayo™ with prior authorization (CVS Caremark, State of Illinois formulary). After the first fill you must enroll in your health plan's lifestyle management program; if you don't, "future coverage will be denied," the state's benefits office says (CMS, Summary of Benefits and Coverage). The law doesn't apply to members in a Medicare Advantage drug plan.
One detail: the law says medical necessity is "determined by a physician licensed to practice medicine in all its branches," which in Illinois means a medical or osteopathic doctor. If a nurse practitioner or physician assistant writes your prescription, ask your plan how it handles the approval. Retiree (TRIP), college (CIP) and local government plans use the same drug list, but their pages don't say whether the weight-loss rule applies, so ask them too (CMS, prescription plan).
Illinois Medicaid: not for weight loss alone
Illinois Medicaid's drug list added Wegovy® and Zepbound® on October 1, 2026 (HFS Preferred Drug List, October 1, 2026), and the current list, effective October 20, 2026, keeps the same three notes: "Wegovy covered for MACE & MASH only," "Zepbound covered for OSA only" and "Wegovy and Zepbound will not be covered for weight loss alone" (HFS Preferred Drug List, October 20, 2026). MACE means heart attack and stroke risk, MASH is a liver disease and OSA is obstructive sleep apnea. Both drugs are non-preferred, so they need prior approval, and the state's rules exclude "Anorectic drugs" (89 Ill. Adm. Code 140.441). GLP-1 drugs for type 2 diabetes stay on the list.
The HealthChoice Illinois plans we could read match it. Aetna Better Health's policy, effective September 1, 2026, calls weight loss only "an excluded benefit" (Aetna Better Health of Illinois policy), and Meridian asks sleep apnea patients to try the Zepbound® KwikPen® first since September 15, 2026 (Meridian).
Blue Cross and Blue Shield of Illinois and other job plans
For most job plans, it's the employer's choice. BCBSIL's October 2026 drug list carries Zepbound®, Wegovy® and Foundayo™ with prior authorization but warns that "Anti-obesity/weight loss/weight management drugs may be excluded" (BCBSIL drug list, October 2026). Its May 20, 2026 notice to self-funded employers calls weight-management coverage "optional." The same notice says the Zepbound® KwikPen®, sold only direct to consumers, "has been excluded from coverage," while the Zepbound® auto-injector stays covered where the employer covers GLP-1s (BCBSIL, May 20, 2026). CVS Caremark, the pharmacy manager for Aetna and many employers, put Zepbound® back on its standard lists on October 1, 2026 "for plan sponsors who elect to provide coverage" (CVS Health, May 28, 2026).
Since January 1, 2026, plans regulated by the state can't make you try another drug first, a rule called step therapy (215 ILCS 134/87). Self-funded employer plans follow federal rules instead.
Get Covered Illinois plans and Health Alliance
Illinois now runs its own marketplace, Get Covered Illinois. The state's benchmark plan, which sets the essential benefits for these plans, excludes "Drugs prescribed and dispensed for the treatment of obesity or for use in any program of weight reduction, weight loss, or dietary control" (CMS, Illinois benchmark plan documents; benchmark summary, 2025 to 2027). A plan may still cover Wegovy® for heart risk or Zepbound® for sleep apnea, so check its drug list. Open enrollment for 2027 runs from November 1, 2026 to January 15, 2027; enroll by December 15 for coverage from January 1 (Get Covered Illinois).
Health Alliance, Carle Health's insurer in Champaign, "ceased operating all lines of business" on January 1, 2026 (Health Alliance), so its members needed new plans and new approvals.
Medicare's $50 GLP-1 Bridge
2,491,519 Illinoisans had Medicare in July 2026 (CMS, Medicare enrollment). Medicare drug plans can't pay for weight loss. But the Medicare GLP-1 Bridge, a CMS program, gives eligible Part D members Wegovy®, Foundayo™ or the Zepbound® KwikPen® for a $50 copay from July 1, 2026 to December 31, 2027 (CMS). It covers the KwikPen® only, not single-dose Zepbound® vials or pens, and never compounded tirzepatide. You need a BMI of 35 or more, or a lower BMI with conditions such as heart failure, prediabetes or a past heart attack or stroke. Your prescriber must also certify a diet and exercise program (Medicare.gov). Any Illinois pharmacy can fill it: "Pharmacies do not need to opt-in" (CMS, information for pharmacies). Free Medicare counseling: the Senior Health Insurance Program (SHIP), 1-800-252-8966 (SHIP, Illinois).
TRICARE at Great Lakes, Scott and Rock Island
TRICARE covers Wegovy®, Zepbound® and Saxenda® for weight management under Prime, Select and most other plans, with prior authorization and "a prescription from a network provider." It doesn't cover them for TRICARE For Life members or people with direct-care-only coverage (TRICARE). That matters around Naval Station Great Lakes near North Chicago, Scott Air Force Base near Belleville and Rock Island Arsenal in the Quad Cities. Illinois had 24,806 active-duty members in 2024 (Defense Department, 2024 demographics).
If your plan says no: Illinois's external review
Appeal to your insurer first. If it still says no, ask for an independent external review within 4 months. A decision comes within 45 days, or 72 hours when your health is at serious risk. The insurer pays for the review and must follow it (Health Carrier External Review Act). It works for a covered drug denied as not medically necessary, such as Wegovy® for heart risk, but it can't overturn a plan's weight-loss exclusion. Medicare, Medicaid, TRICARE, federal employee plans and self-funded job plans have their own appeal routes.